

Mona A Karlsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3655728/publications.pdf>

Version: 2024-02-01

24
papers

674
citations

840776

11
h-index

610901

24
g-index

24
all docs

24
docs citations

24
times ranked

1217
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival in Women Diagnosed With Breast Cancer During Pregnancy. <i>Clinical Breast Cancer</i> , 2022, 22, e517-e525.	2.4	5
2	Cancer in pregnancy and the risk of adverse pregnancy and neonatal outcomes: A nationwide cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 1492-1502.	2.3	11
3	Long-Term Morbidity and Mortality in Children After In Utero Exposure to Maternal Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3975-3984.	1.6	2
4	MicroRNA characteristics in epithelial ovarian cancer. <i>PLoS ONE</i> , 2021, 16, e0252401.	2.5	4
5	Association of Chemotherapy Timing in Pregnancy With Congenital Malformation. <i>JAMA Network Open</i> , 2021, 4, e2113180.	5.9	27
6	Cancer in pregnancy increases the risk of venous thromboembolism: a nationwide cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 1151-1159.	2.3	11
7	Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer. <i>Anticancer Research</i> , 2019, 39, 2475-2482.	1.1	9
8	Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1304-1310.	2.5	1
9	Survival of selected patients with ovarian cancer treated with fertility-sparing surgery. <i>Reproductive BioMedicine Online</i> , 2018, 37, 71-76.	2.4	10
10	Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer. <i>PLoS ONE</i> , 2018, 13, e0207319.	2.5	35
11	Appreciable uncertainty regarding benefits and risks in the treatment of bacterial vaginosis to prevent preterm birth. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2017, 96, 251-252.	2.8	4
12	Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer. <i>PLoS ONE</i> , 2017, 12, e0174300.	2.5	11
13	Treatment of bacterial vaginosis in pregnancy in order to reduce the risk of spontaneous preterm delivery – a clinical recommendation. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2016, 95, 850-860.	2.8	57
14	HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer. <i>Apmis</i> , 2016, 124, 1038-1045.	2.0	10
15	Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT). <i>Gynecologic Oncology</i> , 2016, 142, 50-53.	1.4	33
16	A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage III&IV ovarian cancer – a part of the Danish prospective pelvic mass study. <i>Tumor Biology</i> , 2016, 37, 12619-12626.	1.8	19
17	High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population. <i>Infectious Agents and Cancer</i> , 2016, 11, 39.	2.6	20
18	Primary hyperaldosteronism diagnosed with adrenal vein sampling. Characteristics and follow-up after adrenalectomy in a Danish study. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, 45-50.	1.2	8

#	ARTICLE	IF	CITATIONS
19	The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. <i>Gynecologic Oncology</i> , 2015, 136, 205-211.	1.4	30
20	Serous ovarian, fallopian tube and primary peritoneal cancers: A common disease or separate entities – A systematic review. <i>Gynecologic Oncology</i> , 2015, 136, 571-581.	1.4	27
21	A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer – An international multicenter study in women with an ovarian mass. <i>Gynecologic Oncology</i> , 2015, 138, 640-646.	1.4	78
22	HE4 Tissue Expression and Serum HE4 Levels in Healthy Individuals and Patients with Benign or Malignant Tumors: A Systematic Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2285-2295.	2.5	65
23	Stability of HE4 and CA125 in blood samples from patients diagnosed with ovarian cancer. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2014, 74, 477-484.	1.2	10
24	Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. <i>Gynecologic Oncology</i> , 2012, 127, 379-383.	1.4	187